These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17491549)

  • 1. [The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.1].
    Conti G
    Arch Ital Urol Androl; 2006 Dec; 78(4 Suppl 1):9-10. PubMed ID: 17491549
    [No Abstract]   [Full Text] [Related]  

  • 2. [The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
    Gontero P
    Arch Ital Urol Androl; 2006 Dec; 78(4 Suppl 1):11-2. PubMed ID: 17491550
    [No Abstract]   [Full Text] [Related]  

  • 3. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
    Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
    Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of gemcitabine in the treatment of bladder tumors].
    Cortesi E; Gareri R
    Clin Ter; 1999; 150(1):5-6. PubMed ID: 10367537
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
    Gontero P; Marini L; Frea B
    BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
    [No Abstract]   [Full Text] [Related]  

  • 6. [Metastatic micropapillary variant of urothelial carcinoma of the urinary bladder responding to gemcitabine and cisplatin chemotherapy].
    Ishii T; Matsubara T; Taira H; Hiratsuka Y
    Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):540-4. PubMed ID: 23819368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
    Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
    J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHARMAC's response on gemcitabine and transparency.
    Crausaz S; Metcalfe S
    N Z Med J; 2005 Nov; 118(1225):U1741. PubMed ID: 16286949
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of bladder perfusion of alternating hydroxycamptothecin and gemcitabine combined with low-dose tuberculin in the treatment of non-muscle invasive bladder cancer after TURBT.
    Chen L; Hu W; Li G; Guo Y; Wan Z; Yu J
    J BUON; 2019; 24(4):1652-1658. PubMed ID: 31646821
    [No Abstract]   [Full Text] [Related]  

  • 10. Gemcitabine in bladder cancer.
    El Karak F; Flechon A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Elevation of CA 19.9 in urothelial bladder cancer].
    Bastos Oreiro M; López Rodríguez M; Monedero Martín MC; Plasencia Rodríguez C
    Med Clin (Barc); 2008 Mar; 130(8):319. PubMed ID: 18358126
    [No Abstract]   [Full Text] [Related]  

  • 12. Gemcitabine in the treatment of bladder cancer.
    Ryan CW; Vogelzang NJ
    Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe neurotoxicity caused by gemcitabine treatment.
    Larsen FO; Hansen SW
    Acta Oncol; 2004; 43(6):590-1. PubMed ID: 15370618
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
    Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
    Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
    Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
    J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions for gemcitabine in the treatment of genitourinary cancer.
    Vogelzang NJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):40-5. PubMed ID: 11894007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
    Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
    Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine.
    Simpson A
    N Z Med J; 2005 Nov; 118(1225):U1733. PubMed ID: 16286946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
    Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
    JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
    Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
    J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.